Anavex Life Sciences (NASDAQ:AVXL) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPS

Anavex Life Sciences (NASDAQ:AVXL) announced its quarterly earnings results on Wednesday. The biotechnology company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.03, Zacks reports.

Anavex Life Sciences Price Performance

NASDAQ AVXL opened at $8.70 on Thursday. The firm’s 50-day moving average is $9.92 and its two-hundred day moving average is $7.70. Anavex Life Sciences has a 12 month low of $3.25 and a 12 month high of $14.44. The stock has a market capitalization of $737.93 million, a P/E ratio of -16.73 and a beta of 0.69.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on AVXL. HC Wainwright reissued a “buy” rating and set a $42.00 price target on shares of Anavex Life Sciences in a research report on Tuesday, January 28th. D. Boral Capital reaffirmed a “buy” rating and issued a $46.00 target price on shares of Anavex Life Sciences in a research report on Wednesday.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.